Optimizing First-Line Treatment Options for Patients with Advanced NSCLC

Optimizing First-Line Treatment Options for Patients with Advanced NSCLC Heather Wakelee, Chandra P. Belani Oncologist 2005; 10: 1-10 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the clinical implications of large randomized trials evaluating chemotherapy combinations for patients with advanced NSCLC. Summarize the activity and toxicity of current chemotherapy regimens for the first-line treatment of advanced NSCLC. Describe regimens that have quality-of-life benefits in the treatment of NSCLC. Identify potential future standards of care for advanced disease based on recent research findings evaluating novel targeted agents. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 19, 2005 Most Recent Review: Dec. 19, 2005* Most Recent Update: Dec. 19, 2005 Date Credit Expires: Dec. 19, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.